Chiron grants HCV licence to Rigel Pharmaceuticals
Chiron Corporation has granted a nonexclusive licence to Rigel Pharmaceuticals for the research, development and commercialisation of small molecule therapeutics against certain hepatitis C virus (HCV) drug targets. The financial terms and other details of the license were not disclosed.
Chiron Corporation has granted a nonexclusive licence to Rigel Pharmaceuticals for the research, development and commercialisation of small molecule therapeutics against certain hepatitis C virus (HCV) drug targets. The financial terms and other details of the license were not disclosed.
'This agreement is another example of Chiron's commitment to making its technology widely available to companies that are working to discover therapeutics for hepatitis C,' stated William G. Green, Chiron senior vice president and general counsel. 'We continue to strategically leverage our HCV intellectual property and have an active program to licence this technology to other companies while at the same time pursuing our own research of therapeutic agents for hepatitis C.'